Pyxis Oncology (NASDAQ:PYXS) Coverage Initiated by Analysts at Stifel Nicolaus

Stifel Nicolaus initiated coverage on shares of Pyxis Oncology (NASDAQ:PYXS) in a report issued on Monday. The firm issued a buy rating and a $9.00 price objective on the stock.

A number of other brokerages have also commented on PYXS. Guggenheim started coverage on Pyxis Oncology in a research report on Wednesday, September 3rd. They set a “buy” rating and a $5.00 price objective for the company. Wall Street Zen lowered Pyxis Oncology from a “hold” rating to a “sell” rating in a research report on Friday, October 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Pyxis Oncology in a research report on Wednesday, October 8th. HC Wainwright restated a “buy” rating and set a $5.00 price objective on shares of Pyxis Oncology in a research report on Tuesday, August 19th. Finally, Zacks Research upgraded Pyxis Oncology from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 13th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $8.00.

Pyxis Oncology Stock Performance

NASDAQ PYXS opened at $3.81 on Monday. Pyxis Oncology has a twelve month low of $0.83 and a twelve month high of $5.39. The stock has a market cap of $236.30 million, a price-to-earnings ratio of -2.38 and a beta of 1.40. The firm’s 50 day moving average price is $2.52 and its two-hundred day moving average price is $1.64.

Pyxis Oncology (NASDAQ:PYXS) last released its earnings results on Monday, November 3rd. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.01. On average, research analysts forecast that Pyxis Oncology will post -1.04 EPS for the current fiscal year.

Institutional Investors Weigh In On Pyxis Oncology

Institutional investors have recently made changes to their positions in the company. Catalyst Funds Management Pty Ltd acquired a new stake in shares of Pyxis Oncology during the 2nd quarter valued at about $26,000. Kingstone Capital Partners Texas LLC acquired a new stake in shares of Pyxis Oncology during the 2nd quarter valued at about $37,000. XTX Topco Ltd acquired a new stake in shares of Pyxis Oncology during the 2nd quarter valued at about $40,000. Velan Capital Investment Management LP acquired a new stake in shares of Pyxis Oncology during the 2nd quarter valued at about $44,000. Finally, Bank of America Corp DE lifted its holdings in shares of Pyxis Oncology by 20.3% during the 4th quarter. Bank of America Corp DE now owns 53,745 shares of the company’s stock valued at $84,000 after buying an additional 9,062 shares during the last quarter. 39.09% of the stock is currently owned by institutional investors and hedge funds.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.